An open randomized pilot trial on the differential effects of aripiprazole versus risperidone on anhedonia and subjective well-being

Pharmacopsychiatry

Volumn 44, Issue 3, 2011, Pages 109-113

  Liemburg, E ^a   Aleman, A ^a   Bous, J ^a   Hollander, K ^a   Knegtering, H ^a,b,c  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b UNIVERSITY OF GRONINGEN   (Netherlands)

^c Lentis   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; RISPERIDONE;

ANHEDONIA; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HUMAN; MALE; OPEN STUDY; PRIORITY JOURNAL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; SOCIAL BEHAVIOR; SOCIAL INTERACTION;

ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; DOPAMINE ANTAGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPNOTICS AND SEDATIVES; MALE; MOOD DISORDERS; PERSONAL SATISFACTION; PILOT PROJECTS; PIPERAZINES; PLEASURE; QUINOLONES; RISPERIDONE; SCHIZOPHRENIA;

EID: 79956136363     PISSN: 01763679     EISSN: 14390795     Source Type: Journal    
DOI: 10.1055/s-0031-1271688     Document Type: Article

References (42)

1. Mueser KT, McGurk SR. Schizophrenia. Lancet 2004 363 9426 2063-2072 (Pubitemid 38781110)
2. Andreasen NC. Negative symptoms in schizophrenia. Definition and reliability. Arch Gen Psychiatry 1982 39 784-788 (Pubitemid 12090301)
3. Gold JM, Carpenter C, Randolph TE et al,. Auditory working memory and Wisconsin card sorting test performance in schizophrenia. Arch Gen Psychiatry 1997 54 159-165 (Pubitemid 27074304)
4. Grace AA. Gating of information flow within the limbic system and the pathophysiology of schizophrenia. Brain Res Rev 2000 31 330-341 (Pubitemid 30136188)
5. Abi-Dargham A, Moore H. Prefrontal DA transmission at D1 receptors and the pathology of schizophrenia. Neuroscientist 2003 9 404-416 (Pubitemid 37204344)
6. Jarskog LF, Miyamoto S, Lieberman JA. Schizophrenia: new pathological insights and therapies. Ann Rev Med 2007 58 49-61 (Pubitemid 46706500)
7. Goldman-Rakic PS. Working memory dysfunction in schizophrenia. J Neuropsychiatry Clin Neurosci 1994 6 348-357 (Pubitemid 24344855)
8. Gur RE, Loughhead J, Kohler CG et al,. Limbic activation associated with misidentification of fearful faces and flat affect in schizophrenia. Arch Gen Psychiatry 2007 64 1356-1366 (Pubitemid 350223553)
9. Juckel G, Schlagenhauf F, Koslowski M et al,. Dysfunction of ventral striatal reward prediction in schizophrenia. NeuroImage 2006 29 409-416 (Pubitemid 43063297)
10. Chan HY, Lin WW, Lin SK et al,. Efficacy and safety of aripiprazole in the acute treatment of schizophrenia in Chinese patients with risperidone as an active control: a randomized trial. J Clin Psychiatry 2007 68 29-36
11. Lambert M, Schimmelmann BG, Karow A et al,. Subjective well-being and initial dysphoric reaction under antipsychotic drugs concepts, measurement and clinical relevance. Pharmacopsychiatry 2010 36 suppl 3 181-190
12. Bortolozzi A, Díaz-Mataix L, Toth M et al,. In vivo actions of aripiprazole on serotonergic and dopaminergic systems in rodent brain. Psychopharmacology 2007 191 745-758 (Pubitemid 46355906)
13. Jordan S, Koprivika V, Dunn R et al,. In vivo effects of aripiprazole on cortical and striatal dopaminergic and serotonergic function. Eur J Pharmacol 2004 483 45-53 (Pubitemid 38056603)
14. de Haan L, Booij J, Lavalye J et al,. Occupancy of dopamine D2 receptors by antipsychotic drugs is related to nicotine addiction in young patients with schizophrenia. Psychopharmacology 2006 183 500-505 (Pubitemid 41721152)
15. Brown ES, Nejtek VA, Perantie DC et al,. Cocaine and amphetamine use in patients with psychiatric illness: a randomized trial of typical antipsychotic continuation or discontinuation. J Clin Psychopharmacol 2009 23 384-388
16. Abi-Dargham A, Laruelle M. Mechanisms of action of second generation antipsychotic drugs in schizophrenia: insights from brain imaging studies. Eur Psychiatry 2005 20 15-21
17. Lee MA, Thompson PA, Meltzer HY. Effects of clozapine on cognitive function in schizophrenia. J Clin Pharmacol 1994 55 9 suppl B 82-87 (Pubitemid 24353024)
18. da Silva Alves F, Figee M, van Amelsvoort T et al,. The revised dopamine hypothesis of schizophrenia: evidence from pharmacological MRI studies with atypical antipsychotic medication. Psychopharmacolog Bull 2008 41 121-132
19. Kapur S, Zipursky RB, Jones C et al,. A positron emission tomography study of quetiapine in schizophrenia. Arch Gen Psychiatry 2009 57 553-559
20. Green AI, Zimmet SV, Strous RD et al,. Clozapine for comorbid substance use disorder and schizophrenia: do patients with schizophrenia have a reward-deficiency syndrome that can be ameliorated by clozapine? Harvard Rev Psychiatry 1999 6 287-296 (Pubitemid 29132022)
21. Lambert M, Schimmelmann B, Karow A et al,. Subjective well-being and initial dysphoric reaction under antipsychotic drugs concepts, measurement and clinical relevance. Pharmacopsychiatry 2003 36 suppl 3 S181-S190 (Pubitemid 38085135)
22. van Nimwegen LJ, de Haan L, van Beveren NJM et al,. Effect of olanzapine and risperidone on subjective well-being and craving for cannabis in patients with schizophrenia or related disorders: a double-blind randomized controlled trial. Can J Psychiatry 2008 53 400-405 (Pubitemid 351878642)
23. McGravin JK, Goa KL. Aripiprazole. Adis New Drug Profile 2002 16 779-786 (Pubitemid 35252727)
24. Lieberman JA. Dopamine partial agonists: a new class of antipsychotic 13. CNS Drugs 2004 18 251-267 (Pubitemid 38393435)
25. Semba J, Watanabe A, Kito S et al,. Behavioural and neurochemical effects of OPC-14597, a novel antipsychotic drug, on dopaminergic mechanisms in rat brain. Neuropharmacology 1995 34 785-791
26. Janicak P, Glick I, Marder S et al,. The acute efficacy of aripiprazole across the symptom spectrum of schizophrenia: a pooled post-hoc analysis from 5 short-term studies. J Clin Psychiatry 2009 70 25-35
27. Kane JM, Meltzer HY, Carson WH et al,. Aripiprazole for treatment-resistant schizophrenia: results of a multicenter, randomized, double-blind, comparison study versus perphenazine. J Clin Psychiatry 2007 68 213-223 (Pubitemid 46362642)
28. Riedel M, Schennach-Wolff R, Musil R et al,. Neurocognition and its influencing factors in the treatment of schizophrenia effects of aripiprazole, olanzapine, quetiapine and risperidone. Hum Psychopharmacol 2010 25 116-125
29. Riedel M, Spellman I, Schennach-Wolff R et al,. Effect of aripiprazole on cognition in the treatment of patients with schizophrenia. Pharmacopsychiatry 2010 43 50-57
30. Kane JM. Comparative utility of aripiprazole and haloperidol in schizophrenia: Post-hoc analysis of 52-week, randomized, controlled trials. Appl Health Econ Health Policy 2010 7 109-119
31. de Boer MK, Wiersma D, Bous J et al,. A randomized open-label comparison of the impact of aripiprazole versus risperidone on sexual functioning. J Clin Psychopharmacol 2010 in press
32. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale of schizophrenia. Schizophrenia Bull 1987 13 271-276
33. Naber D, Moritz S, Lambert M et al,. Improvement of schizophrenic patients subjective well-being under atypical antipsychotic drugs. Schizophrenia Res 2001 50 79-88 (Pubitemid 32510889)
34. Wolters HA, Knegtering H, van de Bosch R et al,. Effects and side effects of antipsychotic treatment in schizophrenia: pros and cons of available self-rating scales. Schizophrenia Res 2009 112 114-118
35. Wolters H, Knegtering H, Wiersma D et al,. The spectrum of subjective effects of antipsychotic medication. Acta Neuropsychiatrica 2003 15 274-279 (Pubitemid 37267537)
36. van der Gaag M, Hoffman T, Remijsen M et al,. The five-factor model of the positive and negative syndrome scale II: A ten-fold cross-validation of a revised model. Schizophrenia Res 2006 85 280-287 (Pubitemid 43947530)
37. Li Z, Ichikawa J, Dai J et al,. Aripiprazole, a novel antipsychotic drug, preferentially increases dopamine release in the prefrontal cortex and hippocampus in rat brain. Eur J Pharmacol 2004 493 75-83 (Pubitemid 38746934)
38. Mizrhahi R, Marno D, Rusjan P et al,. The relationship between subjective well-being and dopamine D2 receptors in patients treated with a dopamine partial agonist and full antagonist antipsychotics. Int J Neuropsychopharmacol 2009 1-7
39. McIntyre RS. Aripiprazole for the maintenance treatment of bipolar I disorder: A review. Clin Therapeut 2010 32 S32-S38
40. Pae C-U, Serretti A, Patkar AA et al,. Aripiprazole in the treatment of depressive and anxiety disorders. CNS Drugs 2008 22 367-388 (Pubitemid 351508122)
41. Hertel P. Comparing sertindole to other new generation antipsychotics on preferential dopamine output in limbic versus striatal projection regions: mechanism of action. Synapse 2006 60 543-552 (Pubitemid 44537087)
42. Han M, Hang XF, Deng C. Aripiprazole differentially affects mesolimbic and nigrostriatal dopaminergic transmission: implications for long-term drug efficacy and low extrapyramidal side-effects. Int J Neuropsychopharmacol 2009 12 941-952